ResMed Dirección

Dirección controles de criterios 3/4

El CEO de ResMed's es Mick Farrell , nombrado en Mar 2013, tiene una permanencia de 11.25 años. compensación anual total es $13.87M, compuesta por 8.1% salario y 91.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de MX$1.72B. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 8.6 años, respectivamente.

Información clave

Mick Farrell

Chief Executive Officer (CEO)

US$13.9m

Compensación total

Porcentaje del salario del CEO	8.1%
Permanencia del CEO	11.5yrs
Participación del CEO	0.3%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mick Farrell en comparación con los beneficios de ResMed?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$958m
Dec 31 2023	n/a	n/a	US$890m
Sep 30 2023	n/a	n/a	US$907m
Jun 30 2023	US$14m	US$1m	US$898m
Mar 31 2023	n/a	n/a	US$863m
Dec 31 2022	n/a	n/a	US$809m
Sep 30 2022	n/a	n/a	US$786m
Jun 30 2022	US$12m	US$1m	US$779m
Mar 31 2022	n/a	n/a	US$779m
Dec 31 2021	n/a	n/a	US$522m
Sep 30 2021	n/a	n/a	US$500m
Jun 30 2021	US$10m	US$1m	US$475m
Mar 31 2021	n/a	n/a	US$457m
Dec 31 2020	n/a	n/a	US$699m
Sep 30 2020	n/a	n/a	US$680m
Jun 30 2020	US$10m	US$1m	US$622m
Mar 31 2020	n/a	n/a	US$513m
Dec 31 2019	n/a	n/a	US$455m
Sep 30 2019	n/a	n/a	US$419m
Jun 30 2019	US$10m	US$967k	US$405m
Mar 31 2019	n/a	n/a	US$446m
Dec 31 2018	n/a	n/a	US$450m
Sep 30 2018	n/a	n/a	US$335m
Jun 30 2018	US$9m	US$934k	US$316m

Compensación vs. Mercado: La compensación total de Mick($USD13.87M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD5.85M).

Compensación vs. Ingresos: La compensación de Mick ha sido consistente con los resultados de la empresa en el último año.

CEO

Mick Farrell (52 yo)

11.5yrs

Permanencia

US$13,868,641

Compensación

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Farrell	CEO & Chairman	11.5yrs	US$13.87m	0.32% $ 2.2b
Peter Farrell	Founder	no data	US$680.27k	0.058% $ 404.0m
Brett Sandercock	Chief Financial Officer	18.7yrs	US$3.11m	0.066% $ 457.8m
Robert Douglas	Special Advisor	less than a year	US$6.67m	0.18% $ 1.3b
Kaushik Ghoshal	Chief Commercial Officer - SaaS	2.6yrs	US$3.31m	0.015% $ 103.0m
Alastair Robertson	Chief Information Officer	less than a year	sin datos	sin datos
Amy Wakeham	Chief Investor Relations Officer	1.4yrs	sin datos	sin datos
Michael Rider	Chief Legal Officer	1.2yrs	sin datos	0.0072% $ 49.7m
Jim Ellis	Chief Compliance Officer	6.7yrs	sin datos	sin datos
Yvonne-Katrin Pucknat	Chief Marketing Officer	less than a year	sin datos	sin datos
Vered Keisar	Chief People Officer	3.5yrs	sin datos	sin datos
Hemanth Reddy	Chief Strategy Officer	9.8yrs	sin datos	sin datos

2.6yrs

Permanencia media

60.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RMD * se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Farrell	CEO & Chairman	11.5yrs	US$13.87m	0.32% $ 2.2b
Peter Farrell	Founder	35.3yrs	US$680.27k	0.058% $ 404.0m
Richard Sulpizio	Independent Director	19.1yrs	US$340.06k	0.010% $ 70.7m
Ronald Taylor	Lead Independent Director	19.7yrs	US$372.56k	0.014% $ 98.6m
Jan De Witte	Independent Non-Executive Director	5.3yrs	US$320.06k	0.0039% $ 27.2m
Harjit Gill	Independent Director	5.8yrs	US$320.06k	0.0049% $ 34.0m
Carol Burt	Independent Director	10.8yrs	US$360.06k	0.010% $ 70.5m
Karen Drexler	Independent Director	6.8yrs	US$320.06k	0.0052% $ 35.8m
Desney Tan	Independent Director	2.8yrs	US$320.06k	0.0014% $ 9.8m
John Hernandez	Independent Director	2.8yrs	US$320.06k	0.0014% $ 9.8m

8.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de RMD * se considera experimentada (8.4 años de antigüedad promedio).

ResMed Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold Mex$203m worth of stock

Resmed Inc. Announces Board Changes

Chief Financial Officer recently sold Mex$52m worth of stock

ResMed Inc. Announces Executive Changes

ResMed Inc. Announces Executive Changes

Recent updates

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold Mex$203m worth of stock

Fourth quarter dividend of US$0.53 announced

Full year 2024 earnings released: EPS: US$6.94 (vs US$6.12 in FY 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

ResMed Secures Significant Victory in Patent Fight Against New York University

ResMed Secures Significant Victory in Patent Fight Against New York University

Resmed Inc. Announces Board Changes

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

ResMed Inc. to Report Q1, 2024 Results on Oct 26, 2023

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 21, 2023

ResMed Inc. to Report Q4, 2023 Results on Aug 03, 2023

Chief Financial Officer recently sold Mex$52m worth of stock

ResMed Inc. Announces Executive Changes

ResMed Inc. Announces Executive Changes

Upcoming dividend of US$0.44 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.22 in 3Q 2022)

Independent Director recently sold Mex$2.5m worth of stock

Upcoming dividend of US$0.44 per share at 0.8% yield

Second quarter 2023 earnings released: EPS: US$1.53 (vs US$1.38 in 2Q 2022)

ResMed Inc. Declares Quarterly Dividend, Payable on March 16, 2023

ResMed Inc. to Report Q2, 2023 Results on Jan 26, 2023

Resmed Inc. Appoints Sandeep Gulati as General Manager, South Asia

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 15, 2022

ResMed Inc. to Report Q1, 2023 Results on Oct 27, 2022

ResMed Inc., Annual General Meeting, Nov 16, 2022

ResMed Inc. Announces Cash Dividend for the Quarter of Fiscal Year 2022, Payable on September 22, 2022

ResMed Inc. (NYSE:RMD) acquired mementor DE GmbH.

ResMed Inc. to Report Q4, 2022 Results on Aug 11, 2022

ResMed Announces the Promotion of Lucile Blaise to President of Sleep & Respiratory Care, Effective July 1, 2022

ResMed Inc. (NYSE:RMD) agreed to acquire Medifox-Dan Dresden Gmbh for €950 million.

Investor sentiment deteriorated over the past week

ResMed Inc. Announces Management Changes

Upcoming dividend of US$0.42 per share

Third quarter 2022 earnings released: EPS: US$1.22 (vs US$0.54 loss in 3Q 2021)

ResMed Inc. to Report Q3, 2022 Results on Apr 28, 2022

ResMed Announces Executive Changes

Upcoming dividend of US$0.42 per share

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

ResMed Inc. Announces Ordinary Distribution for the Quarter Ended December 31, 2021, Payable on March 17, 2022

Upcoming dividend of US$0.42 per share

First quarter 2022 earnings released: EPS US$1.40 (vs US$1.23 in 1Q 2021)

Upcoming dividend of US$0.39 per share

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$1.13 profit in 3Q 2020)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 17, 2021

Lead Independent Director recently sold Mex$16m worth of stock

Second quarter 2021 earnings released: EPS US$1.24 (vs US$1.11 in 2Q 2020)

Revenue beats expectations

ResMed Inc.(NYSE:RMD) dropped from S&P 400 Health Care (Sector)

ResMed Inc. to Report Q2, 2021 Results on Jan 28, 2021

Upcoming Dividend of US$0.39 Per Share

First quarter earnings released

First-quarter earnings released: Revenue beats expectations

ResMed Inc. to Report Q1, 2021 Results on Oct 29, 2020

Full year earnings released - EPS Mex$4.31

Earnings released

ResMed Inc. to Report Q4, 2020 Results on Aug 05, 2020

ResMed Inc.(NYSE:RMD) dropped from Russell 1000 Dynamic Index

Análisis de compensación del CEO

CEO

Permanencia